J&J snaps six straight sessions of losses
Contributor since / Followers
Sundry Photography/iStock Editorial via Getty Images
Johnson & Johnson (NYSE:JNJ) shares snapped six straight sessions of losses, as the stock closed 0.5% higher at $161.35 on Thursday.
The healthcare giant lost over 3% in the preceding six sessions. Overall, the stock has gained more than 2% so far this year, compared to the over 20% rise in the broader S&P 500 Index.
JNJ is down 1% over the past one month. The stock closed 1.3% lower on Wednesday at $160.60.
Looking at Seeking Alpha’s Quant Rating, JNJ has a Hold rating with a score of 3.27 out of 5. The company received A+ in the prospect of profitability, while it got F in revisions and growth.
Turning to the Wall Street community, 11 analysts gave JNJ a Buy and above. 12 analysts have given the stock a Hold recommendation, and no one recommended Sell or lower.
Seeking Alpha analysts are also bullish and see the stock as a Buy.
“Johnson & Johnson is regaining momentum with strong growth in its Innovative Medicine and MedTech segments, driven by new products and strategic acquisitions,” said Seeking Alpha analyst Leo Nelissen.
Earlier in the day, a report said that Johnson & Johnson is shuttering its cardiovascular and metabolic drug unit as part of a restructuring of its pharmaceutical division.